Final Deadline for Matrix Claims
Fen-Phen and Redux Litigation. Parker Waichman LLP has been involved in Fen-Phen (fenfluramine/phentermine) and Redux (dexfenfluramine) litigation for many years. These weight loss drugs have become highly scrutinized after evidence revealed that they may cause heart valve damage and pulmonary hypertension. In 1997, the … [Read more...] about Final Deadline for Matrix Claims
Fen-Phen Heart Damage Diagnoses
Fen-Phen Increased Risk Of Heart Damage. The weight-loss drug often referred to as "Fen-Phen" - though it actually was sold under the brand names of Pondimin and Redux - has been associated with an increased risk for heart damage - specifically conditions known as heart valve disease and Primary Pulmonary Hypertension (PPH). Fen-Phen … [Read more...] about Fen-Phen Heart Damage Diagnoses
